Form 8-K - Current report:
SEC Accession No. 0001420720-23-000024
Filing Date
2023-04-03
Accepted
2023-04-03 16:00:19
Documents
13
Period of Report
2023-03-31
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20230331x8k.htm   iXBRL 8-K 31489
  Complete submission text file 0001420720-23-000024.txt   152380

Data Files

Seq Description Document Type Size
2 EX-101.SCH ibio-20230331.xsd EX-101.SCH 4007
3 EX-101.DEF ibio-20230331_def.xml EX-101.DEF 3277
4 EX-101.LAB ibio-20230331_lab.xml EX-101.LAB 13576
5 EX-101.PRE ibio-20230331_pre.xml EX-101.PRE 10171
7 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20230331x8k_htm.xml XML 4623
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 23792513
SIC: 2834 Pharmaceutical Preparations